Table 2 |.

Relative potency at median effective dose.

Compound	ED50 Ratio(HCC1806-Par/MDA-MB-231-Par)	t-value	p-value
neratinib	0.4946 ± 0.2426	−2.0830	4.0220e-2
ceranib-2	0.5165 ± 0.1943	−2.4887	1.4700e-2
CAY10618	0.2089 ± 1.869e-2	−42.3233	1.1593e-59
AZD7762	0.5639 ± 0.1004	−4.3430	3.7500e-5
1S,3R-RSL-3	2.1123 ± 0.4446	2.5244	1.3384e-2
ML162	3.008 ± 0.7041	2.8521	5.4120e-3